Viatris (HAM:VIA) Other Current Receivables: €1,007 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:VIA Viatris Inc HAM:VIA
60 GF Score
Price €14.30
GF Value €9.62
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Viatris Other Current Receivables?

Viatris HAM:VIA +1.33% 60 Other Current Receivables is €1,007 Mil as of Mar. 2026. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.62 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Viatris's Other Current Receivables for the quarter that ended in Mar. 2026 was €1,007 Mil.

Viatris's quarterly Other Current Receivables increased from Sep. 2025 (€575.19 Mil) to Dec. 2025 (€657.15 Mil) and increased from Dec. 2025 (€657.15 Mil) to Mar. 2026 (€1,007.47 Mil).

Viatris's annual Other Current Receivables declined from Dec. 2023 (€1,115.81 Mil) to Dec. 2024 (€808.60 Mil) and declined from Dec. 2024 (€808.60 Mil) to Dec. 2025 (€657.15 Mil).

Viatris Other Current Receivables Related Terms

Viatris Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Viatris's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Other Current Receivables Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 435.42 848.75 1,115.81 808.60 657.15

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 743.33 696.29 575.19 657.15 1,007.47
HAM:VIA
60GF Score
Viatris Inc HAM:VIA
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €1,007 Mil mean?
Viatris (HAM:VIA) has a Other Current Receivables of €1,007 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Viatris and its competitors.
Is Viatris' Other Current Receivables too high?
Viatris' current Other Current Receivables is €1,007 Mil. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Other Current Receivables compare to NBIX and UTHR?
Viatris' Other Current Receivables of €1,007 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Viatris and its competitors. Viatris's current Other Current Receivables is €1,007 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.62, compared to a current price of €14.30 — trading 48.7% above its estimated fair value. The current Other Current Receivables is €1,007 Mil. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Other Current Receivables is €1,007 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €14.30 is trading 48.7% above its estimated GF Value™ of €9.62. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • Other Current Receivables: €1,007 Mil
  • GF Value™: €9.62 vs. price of €14.30 (48.7% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for HAM:VIA

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.30
Price
€9.62
GF Value